- Official Symbol
- SENP2 provided by HGNC
- Official Full Name
- SUMO specific peptidase 2provided by HGNC
- Also known as
- AXAM2; SMT3IP2
- Summary
- SUMO1 (UBL1; MIM 601912) is a small ubiquitin-like protein that can be covalently conjugated to other proteins. SENP2 is one of a group of enzymes that process newly synthesized SUMO1 into the conjugatable form and catalyze the deconjugation of SUMO1-containing species.[supplied by OMIM, Apr 2004]
- Expression. Broad expression in testis (RPKM 37.1), brain (RPKM 13.4) and 24 other tissues
- Preferred Names
- sentrin-specific protease 2
- Names
- SMT3-specific isopeptidase 2
- SUMO1/sentrin/SMT3 specific peptidase 2
- SUMO1/sentrin/SMT3 specific protease 2
- sentrin (SUMO1) specific peptidase 2
- sentrin/SUMO-specific protease SENP2
- Nuclear localization signals: krrr, pakrpr
- Nuclear export signal: lepdlseevsarlrlg
- NR sites: llerl, llqyl
- Conserved Domains (1) summary
-
- COG5160
Location:384 → 589 - ULP1; Protease, Ulp1 family [Posttranslational modification, protein turnover, chaperones]
- COG5160
- The deSUMOylase SENP2 coordinates homologous recombination and nonhomologous end joining by independent mechanisms. Garvin AJ, et al. Genes Dev, 2019 Mar 1. PMID 30796017, Free PMC Article
- SENP2 exerts an anti‑tumor effect on chronic lymphocytic leukemia cells through the inhibition of the Notch and NF‑κB signaling pathways. Chen XL, et al. Int J Oncol, 2019 Feb. PMID 30431078, Free PMC Article
- SUMO1/sentrin/SMT3 specific peptidase 2 modulates target molecules and its corresponding functions. Liu SL, et al. Biochimie, 2018 Sep. PMID 29908207
- The SUMO-specific isopeptidase SENP2 is targeted to intracellular membranes via a predicted N-terminal amphipathic α-helix. Odeh HM, et al. Mol Biol Cell, 2018 Aug 1. PMID 29874116, Free PMC Article
- SUMO-Specific Protease 2 (SENP2) Is an Important Regulator of Fatty Acid Metabolism in Skeletal Muscle. Koo YD, et al. Diabetes, 2015 Jul. PMID 25784542, Free PMC Article
GeneRIFs: Gene References Into Functions
- he nuclear factor (NF)kappaB signaling pathway was also regulated by the overexpression of SENP2. On the whole, the findings of this study indicate that SENP2 can act as a tumor suppressor in CLL cells, and may thus prove to be a novel target for CLL treatment in clinical practice.
- SENP2 is amplified as part of the chromosome 3q amplification in many cancers and Increased SENP2 expression prolongs MDC1 focus retention and increases NHEJ and radioresistance
- SENP2 binds to intracellular membranes where it interacts with membrane-associated proteins and has the potential to regulate their sumoylation and membrane-associated functions.
- research achievements of SENP2 are reviewed in order to understand its related functions and the underlying molecular mechanisms and provide a clue for future research on SENP2
- Quantitative high-throughput screening identifies cytoprotective molecules that enhance SUMO conjugation via the inhibition of SUMO-specific protease (SENP)2.
- Data show that Sentrin/SUMO specific protease (SENP2) interacts with N-myc downstream regulated gene 2 (NDRG2) and mediates the de-SUMOylation process of NDRG2.
- Data demonstrate that downregulation of SENP2 is correlated with poor prognosis in bladder cancer; SENP2 inhibits TGF-beta signaling and TGF-beta-induced EMT of bladder cancer cell; and that its overexpression contributes to suppress bladder cancer cell invasion and metastasis through deSUMOylation of TGF-betaRI.
- The variability of the SENP1 and SENP2 genes may play a role in breast cancer occurrence.
- SENP2 inhibits MMP13 expression in BC cells through de-SUMOylation of TBL1/TBLR1, which inhibits nuclear translocation of beta-catenin.
- miR-181b targets SENP2 and positively regulated NF-kappaB activity. NF-kappaB activation by DNA damage in GBM cells confers resistance to radiation-induced death.
Inga kommentarer:
Skicka en kommentar